Page last updated: 2024-09-04

naproxen and naproxen-n-butyl nitrate

naproxen has been researched along with naproxen-n-butyl nitrate in 59 studies

Compound Research Comparison

Studies (naproxen)	Trials (naproxen)	Recent Studies (post-2010) (naproxen)	Studies (naproxen-n-butyl nitrate)	Trials (naproxen-n-butyl nitrate)	Recent Studies (post-2010) (naproxen-n-butyl nitrate)
4,551	1,057	1,429	63	15	18

Research

Studies (59)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (5.08)	18.2507
2000's	36 (61.02)	29.6817
2010's	20 (33.90)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Adami, A; Benoni, G; Conforti, A; Cuzzolin, L; Del Soldato, P; Lussignoli, S; Menestrina, F	1
Del Soldato, P; McKnight, W; Muscará, MN; Wallace, JL	1
Antonelli, E; Cirino, G; Coata, G; Distrutti, E; Federici, B; Fiorucci, S; Morelli, A; Morelli, O; Renzo, GD; Santucci, L; Soldato, PD	1
Asfaha, S; McKnight, W; Muscará, MN; Wallace, JL	1
Bucci, M; Calignano, A; Cicala, C; Cirino, G; Fiorucci, S; Gerli, R; Ianaro, A; Santucci, L; Wallace, JL	1
Cirino, G; Lovren, F; McKnight, W; Muscará, MN; Triggle, CR; Wallace, JL	1
Monck, N	1
Kalofonos, H; Lebovics, E; Rigas, B; Vagenakis, AG	1
Wallace, JL	1
Atherton, CT; Bebb, JR; Bjarnason, IT; Fagerholm, U; Hawkey, CJ; Jones, JI; Jonzon, B; Karlsson, P; Skelly, MM	1
Berndt, G; Grosser, N; Hoogstraate, J; Schröder, H	2
Berti, F; Del Soldato, P; Manfredi, B; Rossoni, G	1
Cirino, G; Di Lorenzo, A; Farneti, S; Fiorucci, S; Morelli, A; Renga, B	1
Bolin, L; Genti, G; Kalla, A; Lohmander, LS; Malmenäs, M; McKeith, D; Ramos-Remus, C; Svensson, O; Szechinski, J	1
Breese, E; Del Soldato, P; Mitchell, J; Warner, T; Wood, E; Zacharowski, P	1
Adding, LC; Agvald, P; Andersson, LI; Gustafsson, LE; Hoogstraate, J; Jonzon, B	1
Braddock, M	1
Andersson, LI; Brater, DC; Hedman, A; Huledal, G; Jonzon, B; Malmenäs, M; Odlind, B	1
Breuer, O; Fagerholm, U; Hoogstraate, J; Swedmark, S	1
Cochran, ED; Dhawan, V; Earl, RA; Ellis, JL; Garvey, DS; Janero, DR; Khanapure, SP; Letts, LG; Melim, TL; Murty, MG; Selig, WM; Shumway, MJ; Wey, SJ; Young, DV; Zemtseva, IS	1
Whittle, BJ	1
Augustyniak, ME; Cochran, ED; Earl, RA; Ellis, JL; Garvey, DS; Gordon, LJ; Janero, DR; Khanapure, SP; Letts, LG; Melim, TL; Murty, MG; Schwalb, DJ; Selig, WM; Shumway, MJ; Trocha, AM; Young, DV; Zemtseva, IS	1
Hee, A; Kivitz, AJ; Lipetz, RS; Sanders, N; Schnitzer, TJ	1
Björnsson, MA; Fagerholm, U	1
Berti, F; Brini, AT; Clement, MG; De Gennaro Colonna, V; Manfredi, B; Polvani, G; Rossoni, G	1
Fornstedt-Wallin, B; Hedman, A; Jonzon, B; Karlsson, P; Wilder-Smith, CH	1
Cirino, G; Distrutti, E; Wallace, JL	1
Antonelli, E; Fiorucci, S	1
Coulthard, P; Dean, AD; Gerry Cowan, C; Hawkesford, JE; Jeppsson, L; Lamey, PJ; Michael Hill, C; Seymour, RA; Sindet-Pederson, S; Svensson, O; Wickens, M	1
Ji, H; Peng, SX; Zhang, YH	1
Bolla, M; Viappiani, S; Wallace, JL	1
Geusens, P	1
Aguirre, D; Karlsson, J; Pivodic, A; Schnitzer, TJ	1
Beekman, M; Duquesroix, B; Fleming, R; Schnitzer, TJ; White, WB	1
Bjarnason, I; Hotz-Behofsits, C; Sigthorsson, G; Simpson, R; Walley, M	1
Boring, D; Grubbs, CJ; Juliana, MM; Kopelovich, L; Lubet, RA; Patlolla, J; Rao, CV; Steele, VE; Zhang, Y	1
Duquesroix, B; Frayssinet, H; Kivitz, A; Schnitzer, TJ	1
Boring, D; Chattopadhyay, M; Crowell, JA; Goswami, S; Kashfi, K; Kodela, R; Rodes, DB; Velazquez, CA	1
Du, H; Ji, L; Li, LP; Prasad, PV; Schnitzer, T	1
Baerwald, C; Duquesroix, B; Ferreira, T; Frayssinet, H; Verdecchia, P	1
Beekman, M; Duquesroix, B; Frayssinet, H; Hochberg, MC; Marrero, CE; Schnitzer, TJ	1
Björnsson, MA; Simonsson, US	1
Bakris, GL; Duquesroix, B; Frayssinet, H; Schnitzer, TJ; Weber, M; White, WB	1
Cao, L; Du, Y; Li, L; Shi, X; Xue, N; Yuan, Z; Zhang, K	1
Dzielska-Olczak, M	1
Bittar, N; Chrysant, SG; Djian, J; Duquesroix, B; Pivodic, A; Ramsay, A; Rosen, J; Smith, W; Townsend, R; Weiss, R	1
Bond, M; Davis, A; Hawker, G; Lohmander, S	1
Bode, AM; Boring, D; Grubbs, CJ; Kim, MS; Lu, Y; Lubet, RA; Margaret Juliana, M; Milne, GL; Nicastro, HL; Steele, VE; You, M	1
Atkinson, TJ; Fudin, J; Jahn, HL; Kubotera, N; Rennick, AL; Rhorer, M	1
Gordish-Dressman, H; Miglietta, D; Miller, BK; Nagaraju, K; Ongini, E; Phadke, A; Quinn, JL; Tatem, KS; Uaesoontrachoon, K; Van Der Meulen, JH; Yu, Q	1
Borhade, N; Burhan, A; Desai, DC; Dhiman, M; Gaikwad, P; Gund, M; Nemmani, KVS; Patil, M; Satyam, A; Sharma, A; Sharma, S; Sheikh, J; Thakre, G; Tipparam, SG	1
Cao, D; Du, Y; Hao, Y; Shang, W; Shi, Q; Shi, X; Sun, M; Wang, S; Wang, Y; Xue, N; Zhang, K	1
Anzini, M; Belmonte, G; Biava, M; Cheleschi, S; Di Capua, A; Fioravanti, A; Giordani, A; Pascarelli, NA; Sticozzi, C; Valacchi, G	1
Clementi, E; De Palma, C; Miglietta, D; Ongini, E; Pisa, V; Sciorati, C; Vergani, B; Villa, A	1
Aisa, MC; Datti, A; Di Renzo, GC; Orlacchio, A	1

Reviews

12 review(s) available for naproxen and naproxen-n-butyl nitrate

Article	Year
NO-naproxen (AstraZeneca). IDrugs : the investigational drugs journal, 2003, Volume: 6, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Humans; Naproxen; Nitric Oxide; Nitric Oxide Donors; Pain; Structure-Activity Relationship	2003
NO-NSAIDs and cancer: promising novel agents. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2003, Volume: 35 Suppl 2 Topics: Animal Experimentation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cell Line, Tumor; Humans; In Vitro Techniques; Naproxen; Nitric Oxide; Rats	2003
Nitric oxide-releasing mesalamine: potential utility for treatment of inflammatory bowel disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2003, Volume: 35 Suppl 2 Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Colitis; Cytokines; Disease Models, Animal; Humans; Leukocytes; Mesalamine; Naproxen; Nitric Oxide; Rats	2003
Nitric oxide-modulating agents for gastrointestinal disorders. Expert opinion on investigational drugs, 2005, Volume: 14, Issue:11 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Enteritis; Esophagus; Fissure in Ano; Gastric Emptying; Gastrointestinal Diseases; Gastrointestinal Motility; Humans; Naproxen; Nitrates; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase Type II; Peroxynitrous Acid	2005
Nitric oxide and inflammation. Inflammation & allergy drug targets, 2006, Volume: 5, Issue:2 Topics: Acetaminophen; Animals; Anti-Inflammatory Agents; Aspirin; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Inflammation; Naproxen; Nitrates; Nitric Oxide	2006
NO-NSAIDs: from inflammatory mediators to clinical readouts. Inflammation & allergy drug targets, 2006, Volume: 5, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Blood Coagulation; Cardiovascular Diseases; Chemotaxis, Leukocyte; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Cytokines; Endothelial Cells; Gastrointestinal Tract; Gene Expression Regulation; Humans; Leukocytes; Macrophages; Mitochondria; Naproxen; Nitrates; Nitric Oxide; Nitric Oxide Synthase Type II; Platelet Aggregation	2006
Nitronaproxen: AZD 3582, HCT 3012, Naproxen Nitroxybutylester, NO-Naproxen. Drugs in R&D, 2006, Volume: 7, Issue:4 Topics: Animals; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation, Preclinical; Humans; Naproxen; Nitric Oxide; Placebos; Randomized Controlled Trials as Topic; Rheumatic Diseases	2006
Naproxcinod: AZD 3582, HCT 3012, naproxen nitroxybutylester, nitronaproxen, NO-naproxen. Drugs in R&D, 2007, Volume: 8, Issue:4 Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Humans; Naproxen; Nitric Oxide Donors; Osteoarthritis; Terminology as Topic; Treatment Outcome	2007
[A novel class of anti-inflammatory and analgesic drugs--NO-donating NSAIDs]. Yao xue xue bao = Acta pharmaceutica Sinica, 2007, Volume: 42, Issue:4 Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiotonic Agents; Cyclooxygenase Inhibitors; Flurbiprofen; Gastrointestinal Diseases; Humans; Ibuprofen; Naproxen; Nitrates; Nitric Oxide Donors	2007
Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert opinion on biological therapy, 2009, Volume: 9, Issue:5 Topics: Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Naproxen; Nitric Oxide Donors; Osteoarthritis	2009
[Cyclooxygenases inhibitors and other compounds with antiinflammatory potential in osteoarthrosis--part II]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2011, Volume: 30, Issue:175 Topics: Animals; Anti-Inflammatory Agents; Aspirin; Cyclooxygenase Inhibitors; Drug Interactions; Humans; Naproxen; Nitric Oxide Donors; Osteoarthritis	2011
What's new in NSAID pharmacotherapy: oral agents to injectables. Pain medicine (Malden, Mass.), 2013, Volume: 14 Suppl 1 Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Humans; Hyaluronic Acid; Hydrogen Sulfide; Ibuprofen; Injections; Injections, Intra-Articular; Isoxazoles; Nanoparticles; Naproxen; Nitric Oxide Donors; Vasodilator Agents	2013

Trials

15 trial(s) available for naproxen and naproxen-n-butyl nitrate

Article	Year
Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut, 2003, Volume: 52, Issue:11 Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cell Membrane Permeability; Cross-Over Studies; Cyclooxygenase Inhibitors; Double-Blind Method; Duodenal Diseases; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Naphthalenes; Naproxen; Nitric Oxide Donors; Stomach Diseases	2003
A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Annals of the rheumatic diseases, 2005, Volume: 64, Issue:3 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Naphthalenes; Naproxen; Osteoarthritis, Hip; Osteoarthritis, Knee; Peptic Ulcer; Quality of Life; Treatment Outcome	2005
Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. Clinical pharmacology and therapeutics, 2005, Volume: 77, Issue:5 Topics: Adult; Area Under Curve; Blood Pressure; Cyclooxygenase Inhibitors; Diet, Sodium-Restricted; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Humans; Iohexol; Lactones; Male; Naphthalenes; Naproxen; Nitric Oxide Donors; Potassium; Renin; Sodium; Sulfones	2005
Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee. Arthritis and rheumatism, 2005, Dec-15, Volume: 53, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lactones; Male; Middle Aged; Naphthalenes; Naproxen; Osteoarthritis, Knee; Pain Measurement; Severity of Illness Index; Sulfones; Surveys and Questionnaires; Treatment Outcome	2005
Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects. Scandinavian journal of gastroenterology, 2006, Volume: 41, Issue:3 Topics: Adult; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Humans; Intestinal Mucosa; Male; Naphthalenes; Naproxen; Reference Values; Stomach Ulcer; Thromboxane B2; Treatment Outcome	2006
Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies. Clinical therapeutics, 2006, Volume: 28, Issue:9 Topics: Adolescent; Adult; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lactones; Male; Mandible; Middle Aged; Molar, Third; Naphthalenes; Naproxen; Pain Measurement; Pain, Postoperative; Sulfones; Tooth Extraction; Treatment Outcome	2006
Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. The Journal of rheumatology, 2009, Volume: 36, Issue:6 Topics: Aged; Antirheumatic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Naproxen; Nitric Oxide Donors; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain; Pain Measurement; Severity of Illness Index; Treatment Outcome	2009
Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. The American journal of cardiology, 2009, Sep-15, Volume: 104, Issue:6 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Comorbidity; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Naproxen; Nitric Oxide Donors; Osteoarthritis	2009
Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study. Osteoarthritis and cartilage, 2010, Volume: 18, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Rate; Humans; Male; Middle Aged; Naproxen; Nitric Oxide Donors; Osteoarthritis, Knee; Pain; Pain Measurement; Prospective Studies; Severity of Illness Index	2010
Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. Arthritis and rheumatism, 2010, Volume: 62, Issue:12 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis, Hip; Pain Measurement; Treatment Outcome	2010
Efficacy and safety of naproxcinod in patients with osteoarthritis of the knee: a 53-week prospective randomized multicenter study. Seminars in arthritis and rheumatism, 2011, Volume: 40, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Double-Blind Method; Female; Humans; Male; Middle Aged; Naproxen; Nitric Oxide Donors; Osteoarthritis, Knee; Pain; Pain Measurement; Prospective Studies; Treatment Outcome	2011
Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration. British journal of clinical pharmacology, 2011, Volume: 71, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Female; Humans; Male; Molar, Third; Naproxen; Pain Measurement; Pain, Postoperative; Tooth Extraction; Young Adult	2011
Effects of naproxcinod on blood pressure in patients with osteoarthritis. The American journal of cardiology, 2011, May-01, Volume: 107, Issue:9 Topics: Aged; Blood Pressure; Double-Blind Method; Female; Humans; Male; Middle Aged; Naproxen; Nitric Oxide Donors; Osteoarthritis; Treatment Outcome	2011
Blood pressure effects of naproxcinod in hypertensive patients. Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:5 Topics: Aged; Blood Pressure; Cross-Over Studies; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Naproxen; Nitric Oxide Donors; Treatment Outcome	2011
Responsiveness of the OARSI-OMERACT osteoarthritis pain and function measures. Osteoarthritis and cartilage, 2012, Volume: 20, Issue:6 Topics: Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Nitric Oxide Donors; Osteoarthritis, Hip; Osteoarthritis, Knee; Pain; Pain Measurement; Severity of Illness Index; Treatment Outcome	2012

Other Studies

32 other study(ies) available for naproxen and naproxen-n-butyl nitrate

Article	Year
Anti-inflammatory potency and gastrointestinal toxicity of a new compound, nitronaproxen. Pharmacological research, 1995, Volume: 31, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Carrageenan; Digestive System; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Female; Male; Naproxen; Rats; Rats, Sprague-Dawley; Stomach Ulcer	1995
Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life sciences, 1998, Volume: 62, Issue:15 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Gastric Mucosa; Hypertension; Male; Naproxen; NG-Nitroarginine Methyl Ester; Nitric Oxide; Rats; Rats, Wistar; Stomach Ulcer; Thromboxane B2	1998
Nitric oxide-releasing NSAIDs inhibit interleukin-1beta converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFalpha. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Caspase Inhibitors; Cell Line; Cysteine Proteinase Inhibitors; DNA Fragmentation; Endothelium, Vascular; Flurbiprofen; Gastric Mucosa; Humans; In Situ Nick-End Labeling; Male; Mice; Naproxen; Nitric Oxide; Peroxidase; Rats; Rats, Wistar	1999
Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. British journal of pharmacology, 2000, Volume: 129, Issue:4 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Collagen; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Exudates and Transudates; Gastric Mucosa; Inflammation; Isoenzymes; Male; Membrane Proteins; Naproxen; Nitrates; Nitric Oxide Donors; Nitrites; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Thromboxanes; Wound Healing	2000
NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. British journal of pharmacology, 2000, Volume: 130, Issue:6 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Dose-Response Relationship, Drug; Edema; Flow Cytometry; Hindlimb; Inflammation; Interleukin-1; Male; Naproxen; Nitric Oxide; Nociceptors; Pain; Pain Measurement; Rats; Rats, Inbred Lew; Receptors, Interleukin-2; T-Lymphocytes; Thymidine; Time Factors; Tumor Necrosis Factor-alpha	2000
Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. American journal of physiology. Heart and circulatory physiology, 2000, Volume: 279, Issue:2 Topics: Animals; Aorta, Thoracic; Blood Pressure; Endothelin-1; Hypertension, Renovascular; In Vitro Techniques; Isometric Contraction; Male; Muscle, Smooth, Vascular; Naproxen; Nitrates; Nitric Oxide Donors; Nitrites; Nitroglycerin; Nitroprusside; Phenylephrine; Rats; Rats, Wistar; Renal Artery; Thromboxane B2	2000
A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2004, Volume: 21, Issue:2-3 Topics: Animals; Cyclic GMP; Cyclooxygenase Inhibitors; LLC-PK1 Cells; Molsidomine; Naphthalenes; Naproxen; Nitric Oxide; Nitric Oxide Donors; Nitroglycerin; Swine	2004
The nitric oxide-releasing naproxen derivative displays cardioprotection in perfused rabbit heart submitted to ischemia-reperfusion. The Journal of pharmacology and experimental therapeutics, 2004, Volume: 310, Issue:2 Topics: Animals; Cardiotonic Agents; Heart; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Naproxen; Nitric Oxide; Rabbits	2004
Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO The Journal of pharmacology and experimental therapeutics, 2004, Volume: 311, Issue:3 Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Eicosanoids; Freund's Adjuvant; Gastric Mucosa; Isoenzymes; Lipoxins; Male; Membrane Proteins; Naproxen; Nitric Oxide; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Rats; Rats, Inbred Lew; Reverse Transcriptase Polymerase Chain Reaction; Stomach Ulcer; Sulfonamides	2004
NSAIDs increase GM-CSF release by human synoviocytes: comparison with nitric oxide-donating derivatives. European journal of pharmacology, 2005, Jan-31, Volume: 508, Issue:1-3 Topics: 1-Methyl-3-isobutylxanthine; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blotting, Western; Cells, Cultured; Cyclic AMP; Cyclic GMP; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Flurbiprofen; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indomethacin; Membrane Proteins; Naproxen; Nitric Oxide Donors; Nitroprusside; Phosphodiesterase Inhibitors; Prostaglandin-Endoperoxide Synthases; Purinones; Synovial Membrane; Time Factors	2005
Direct gas measurements indicate that the novel cyclooxygenase inhibitor AZD3582 is an effective nitric oxide donor in vivo. British journal of pharmacology, 2005, Volume: 145, Issue:5 Topics: Acid-Base Equilibrium; Air; Animals; Blood Pressure; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Gases; Heart Rate; Hemoglobins; In Vitro Techniques; Male; Naphthalenes; Naproxen; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitroglycerin; Prostaglandin-Endoperoxide Synthases; Rabbits; Vasodilator Agents	2005
AntiArthritis Therapies 2005. Expert opinion on investigational drugs, 2005, Volume: 14, Issue:4 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antirheumatic Agents; Arthritis; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Design; Drug Evaluation, Preclinical; Humans; Infliximab; Naproxen; Nitric Oxide Donors; Rituximab; Tumor Necrosis Factor-alpha	2005
Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582. The Journal of pharmacy and pharmacology, 2005, Volume: 57, Issue:5 Topics: Animals; Bile; Biological Availability; Blood Proteins; Cyclooxygenase Inhibitors; Cytochrome P-450 Enzyme System; Dogs; Drug Evaluation, Preclinical; Drug Stability; Female; Humans; In Vitro Techniques; Intestinal Absorption; Male; Milk; Naphthalenes; Naproxen; Nitric Oxide Donors; Protein Binding; Rabbits; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Species Specificity; Swine; Swine, Miniature; Tissue Distribution	2005
AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2005, Volume: 25, Issue:2-3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Blotting, Northern; Cell Line; Cyclooxygenase Inhibitors; Endothelial Cells; Gastric Mucosa; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Membrane Proteins; Naphthalenes; Naproxen; Nitric Oxide Donors; Reactive Oxygen Species; RNA, Messenger	2005
A comparison of the cyclooxygenase inhibitor-NO donors (CINOD), NMI-1182 and AZD3582, using in vitro biochemical and pharmacological methods. Biochemical pharmacology, 2005, Nov-01, Volume: 70, Issue:9 Topics: Cyclic GMP; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Liver; Naphthalenes; Naproxen; Nitric Oxide; Nitric Oxide Donors	2005
NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology, 2005, Volume: 12, Issue:5-6 Topics: Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Edema; Gastric Mucosa; Humans; In Vitro Techniques; Inflammation; Male; Molecular Structure; Naphthalenes; Naproxen; Neutrophil Infiltration; Nitric Oxide Donors; Protective Agents; Rats; Rats, Sprague-Dawley; Vasodilation	2005
Clinical pharmacokinetics of the cyclooxygenase inhibiting nitric oxide donator (CINOD) AZD3582. The Journal of pharmacy and pharmacology, 2005, Volume: 57, Issue:12 Topics: Cyclooxygenase Inhibitors; Half-Life; Humans; Intestinal Absorption; Naphthalenes; Naproxen; Nitric Oxide Donors	2005
Nitric oxide and prostacyclin pathways: an integrated mechanism that limits myocardial infarction progression in anaesthetized rats. Pharmacological research, 2006, Volume: 53, Issue:4 Topics: Animals; Arginine; Arrhythmias, Cardiac; Cardiotonic Agents; Creatine Kinase; Epoprostenol; Isosorbide Dinitrate; Male; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Naproxen; Nitric Oxide; Peroxidase; Polydeoxyribonucleotides; Random Allocation; Rats; Rats, Wistar; Thromboxane B2	2006
Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends in pharmacological sciences, 2009, Volume: 30, Issue:3 Topics: Animals; Blood Pressure; Cardiovascular System; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Naproxen; Nitric Oxide Donors; Osteoarthritis	2009
The effects of AZD3582 [4-(nitroxy)butyl-(2S)-2-(6-methoxy-2-naphthyl) propanoate], and naproxen on key pathogenic steps in NSAID-enteropathy in the rat. Inflammopharmacology, 2007, Volume: 15, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Enteritis; Intestinal Diseases; Male; Naproxen; Nitric Oxide Donors; Permeability; Rats; Rats, Sprague-Dawley; Ulcer	2007
Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:11 Topics: Alkylating Agents; Animals; Anti-Inflammatory Agents, Non-Steroidal; Azoxymethane; Butylhydroxybutylnitrosamine; Carcinogens; Colonic Neoplasms; Diet; Female; Male; Mammary Neoplasms, Experimental; Methylnitrosourea; Naproxen; Nitric Oxide Donors; Precancerous Conditions; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Urinary Bladder Neoplasms	2009
NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation. Cancer letters, 2010, Dec-08, Volume: 298, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blotting, Western; Caspase 3; Cell Proliferation; Colonic Neoplasms; Dinoprostone; Dose-Response Relationship, Drug; Gastric Mucosa; HT29 Cells; Humans; Male; Naproxen; NF-kappa B; Nitrates; Nitric Oxide; Nitric Oxide Donors; Rats; Rats, Wistar; S-Nitrosothiols; Signal Transduction; Stomach; Transcription Factor RelA; Tumor Necrosis Factor-alpha	2010
Intra-renal oxygenation in rat kidneys during water loading: effects of cyclooxygenase (COX) inhibition and nitric oxide (NO) donation. Journal of magnetic resonance imaging : JMRI, 2010, Volume: 32, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Hypoxia; Kidney; Male; Naproxen; Nitric Oxide; Nitric Oxide Donors; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Rats; Rats, Sprague-Dawley; Water	2010
Separation of the two enantiomers of naproxcinod by chiral normal-phase liquid chromatography. Journal of chromatographic science, 2011, Volume: 49, Issue:4 Topics: 2-Propanol; Chromatography, High Pressure Liquid; Hexanes; Linear Models; Naproxen; Reproducibility of Results; Sensitivity and Specificity; Stereoisomerism	2011
Naproxcinod. Prescrire international, 2012, Volume: 21, Issue:129 Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Naproxen; Nitric Oxide Donors; Osteoarthritis	2012
Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model. Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Chemoprevention; Drug Evaluation, Preclinical; Eflornithine; Female; Naproxen; Neoplasms, Experimental; Nitric Oxide; Rats; Rats, Inbred F344; Sulindac; Urinary Bladder Neoplasms	2014
Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy. Human molecular genetics, 2014, Jun-15, Volume: 23, Issue:12 Topics: Animals; Anti-Inflammatory Agents; Body Weight; Disease Models, Animal; Dose-Response Relationship, Drug; Heart Function Tests; Hindlimb; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle, Skeletal; Muscular Dystrophy, Duchenne; Naproxen; Nitric Oxide Donors; Prednisolone	2014
Gastric-sparing nitric oxide-releasable 'true' prodrugs of aspirin and naproxen. Bioorganic & medicinal chemistry letters, 2014, Dec-15, Volume: 24, Issue:24 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Aspirin; Blood Platelets; Cyclooxygenase 1; Cyclooxygenase 2; Drug Design; Drug Stability; Gastric Mucosa; Half-Life; Humans; Naproxen; Nitrates; Nitric Oxide; Platelet Aggregation Inhibitors; Prodrugs; Rats; Rats, Sprague-Dawley; ROC Curve; Thromboxane B2	2014
Simultaneous quantification of naproxcinod and its active metabolite naproxen in rat plasma using LC-MS/MS: application to a pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015, Jan-26, Volume: 978-979 Topics: Animals; Chromatography, Liquid; Drug Stability; Linear Models; Male; Naproxen; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry	2015
Chondroprotective effect of three different classes of anti-inflammatory agents on human osteoarthritic chondrocytes exposed to IL-1β. International immunopharmacology, 2015, Volume: 28, Issue:1 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cell Culture Techniques; Cell Survival; Cells, Cultured; Chondrocytes; Cyclooxygenase 2; Dinoprostone; Dose-Response Relationship, Drug; Gene Expression; Humans; Interleukin-1beta; Matrix Metalloproteinases; Middle Aged; Molecular Structure; Naproxen; NF-kappa B; Nitrates; Osteoarthritis, Hip; Pyrroles	2015
Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy. Orphanet journal of rare diseases, 2015, Aug-22, Volume: 10 Topics: Animals; Biological Availability; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscular Dystrophy, Duchenne; Naproxen; Nitric Oxide Donors	2015
COX inhibitors and bone: A safer impact on osteoblasts by NO-releasing NSAIDs. Life sciences, 2018, Sep-01, Volume: 208 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bone Neoplasms; Cathepsin B; Cell Differentiation; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Humans; Metalloproteases; Naproxen; Nitric Oxide; Osteoblasts; Osteosarcoma; Plasminogen Activators; Tumor Cells, Cultured	2018